81 followers
@BiotechObserver @jq1234t @bradloncar .@BiotechObserver here are the mosun (roche 1:1 format) data from ASH last year. Much lower CRS rates (21%), which might be due to step-dosing approach. https://t.co/aLJWapk3Sd
ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL)
Overview of attention for article published in Hematological Oncology, June 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (73rd percentile)
-
Good Attention Score compared to outputs of the same age and source (79th percentile)
Readers on
- mendeley
- 10 Mendeley